Toxic epidermal necrosis - Epidermalibus Toxicus Necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Epidermalibus Toxicus Necrosis (Toxic epidermal necrosis) genus est reactionis cutis gravibus. Signa prima includunt febres et symptomata fluviatiles. Paucis post diebus cutis pustula incipit et cortices areae squamosas formans dolentes. Aliquam sit amet membranae mucosae, ut os, saepe involvantur. Complicationes includunt siccitatibus, sepsis, pneumonia et multiplici defectu organi.

Frequentissima causa est quaedam medicamenta, ut lamotrigine, carbamazepino, allopurinolo, sulfonamide antibiotico, et nevirapino. Periculum factores comprehendunt HIV et lupus erythematosus systemicus. Curatio typice locum habet in valetudinariis, sicut in combustione unitatis vel intensiva cura unitatis.

Curatio
Gravis hic morbus est, ut si labia tua vel os adficiantur vel cutis tua pusulata sit, medicum videas quam primum.
Suspiciosa medicamenta intermitti debent. (v.g. antibiotica, non-steroidales medicamenta inflammationis anti-inflammatoriae)

☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
  • Epidermalibus Toxicus Necrosis (Toxic epidermal necrosis) damnum cutis propria est
  • TENS die 10
  • Necrolysis epidermalis toxica
  • Maculae praemature celeriter progredi possunt ut intra paucos dies totum corpus involvat.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) et Toxic Epidermal Necrolysis (TEN) rarae condiciones sunt ubi cutis amplam necrosim et effusionem experitur. In terminis curationis, cyclosporinum maxime efficax est pro SJS, dum coniunctio immunoglobulin intravenous (IVIg) et corticosteroides optime pro casibus SJS et DECEM operatur.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) Gravis reactiones pelliculae causatur per medicamenta quaedam et activitatem immunem, inde in magna-scalarum elongatione strato exterioris (epidermis) , plus quam 30% superficiei corporis afficiens. DECEM habet mortalitatem plus quam viginti%, saepe ob infectiones et difficultates spirandi. Sistit medicinam faciens reactionem, curas adminiculas praebens, et curationes adiectis utens eventum emendare potest. Recentes studiis docuerunt medicamenta instar cyclosporini, tumoris necrosis factoris alpha inhibitores, et coniunctio globulorum intravenorum immunis et corticosteroides utiles esse posse, innixa in iudiciis moderatis et multiplicium studiorum analysibus randomized.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.